Tracking blood markers in aggressive Hodgkin and non-Hodgkin lymphoma
A Prospective Study for Patients With Lymphoma at the Samsung Medical Center
This project will try to use blood tests (serum and cell-free DNA) to track treatment response and outcomes for adults with aggressive Hodgkin or non-Hodgkin lymphoma.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Sex | All |
| Sponsor | Samsung Medical Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Seoul) |
| Trial ID | NCT07032103 on ClinicalTrials.gov |
What this trial studies
This is a prospective cohort of adults with aggressive lymphomas who are receiving systemic chemotherapy at Samsung Medical Center. Patients may be newly diagnosed or have relapsed/refractory disease and will receive routine care per institutional practice. Researchers will collect serum and cell-free DNA from peripheral blood at baseline, interim, end of treatment, and at relapse, alongside standard laboratory and imaging assessments. Disease response and survival status will be updated regularly to correlate blood-based markers with clinical outcomes.
Who should consider this trial
Good fit: Adults aged 20 or older with pathologically confirmed Hodgkin or non-Hodgkin aggressive lymphoma who require systemic chemotherapy with curative intent are ideal candidates.
Not a fit: Patients with myeloid malignancies, multiple myeloma, those who do not require systemic chemotherapy with curative intent, or patients under 20 are not expected to benefit from this project.
Why it matters
Potential benefit: If successful, the study could identify blood-based markers that help predict treatment response and relapse, enabling earlier intervention and more personalized follow-up.
How similar studies have performed: Previous work has shown circulating tumor DNA and other blood markers can track disease and predict relapse in lymphoma, but their routine clinical use is still emerging.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas 2. 20 years 3. Patients requiring systemic chemotherapy with curative intent 4. Written informed consent Exclusion Criteria: 1. Myeloid malignancy 2. Multiple myeloma 3. Patients do not require systemic chemotherapy with curative intent
Where this trial is running
Seoul
- Samsung Medical Center — Seoul, South Korea (Recruiting)
Study contacts
- Study coordinator: Seok Jin Kim, MD., PhD.
- Email: kstwoh@gmail.com
- Phone: +82234101766
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.